IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism

Journal of Immunology

Volumn 170, Issue 7, 2003, Pages 3890-3897

  Rendon Mitchell, Beatriz ^b   Ochani, Mahendar ^b   Li, Jianhua ^b   Han, Jialian ^b   Wang, Hong ^b   Yang, Huan ^b   Susarla, Seenu ^b   Czura, Christopher ^b   Mitchell, Robert A ^b   Chen, Guoqian ^a   Sama, Andrew E ^a   Tracey, Kevin J ^b   Wang, Haichao ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b N Shore Long Isl Jewish Res Inst ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NEUTRALIZING ANTIBODY; NITRIC OXIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; KNOCKOUT GENE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION;

EID: 0141830087     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.7.3890     Document Type: Article

References (70)

1. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2000. Cytokine signaling: regulation of the immune response in normal and critically ill states. Crit. Care Med. 28:N3.
2. Wang, H., and K. J. Tracey. 1999. TNF, IL-6, MIF and MIP-1 in inflammation. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin and R. Snyderman, eds. Lippincott-Raven, Philadelphia, p. 471.
3. Wang, H., O. Bloom, M. Zhang, J. M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248.
4. Wang, H., H. Yang, C. J. Czura, A. E. Sama, and K. J. Tracey. 2001. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164:1768.
5. Johns, E. W. 1982. History, definitions and problems. In The HMG Chromosomal Proteins. E. W. Johns, ed. Academic, London. p. 1.
6. Bustin, M. 1999. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19:5237.
7. Wang, H., C. J. Czura, and K. J. Tracey. 2003. HMGB1. In The Cytokine Handbook. A. Thomson and M. T. Lotze, eds. Academic, Oxford. In press.
8. Merenmies, J., R. Pihlaskari, J. Laitinen, J. Wartiovaara, and H. Rauvala. 1991. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth: amino acid sequence and localization in the filopodia of the advancing plasma membrane. J. Biol. Chem. 266:16722.
9. Taguchi, A., D. C. Blood, G. del Toro, A. Canet, D. C. Lee, W. Qu, N. Tanji, Y. Lu, E. Lalla, C. Fu, et al. 2000. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354.
10. Hori, O., J. Brett, T. Slattery, R. Cao, J. Zhang, J. X. Chen, M. Nagashima, E. R. Lundh, S. Vijay, and D. Nitecki. 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752.
11. Degryse, B., T. Bonaldi, P. Scaffidi, S. Muller, M. Resnati, F. Sanvito, G. Arrigoni, and M. E. Bianchi. 2001. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152:1197.
12. Ombrellino, M., H. Wang, M. S. Ajemian, A. Talhouk, L. A. Scher, S. G. Friedman, and K. J. Tracey. 1999. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 354:1446.
13. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191.
14. Sappington, P. L., R. Yang, H. Yang, K. J. Tracey, R. L. Delude, and M. P. Fink. 2002. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and causes derangements in intestinal barrier function in mice. Gastroenterology 123:790.
15. Abraham, E., J. Arcaroli, A. Carmody, H. Wang, and K. J. Tracey. 2000. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165:2950.
16. Andersson, U., H. Wang, K. Palmblad, A. C. Aveberger, O. Bloom, H. Erlandsson-Harris, A. Janson, R. Kokkola, M. Zhang, H. Yang, and K. J. Tracey. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192:565.
17. Agnello, D., H. Wang, H. Yang, K. J. Tracey, and P. Ghezzi. 2002. HMGB1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 18:231.
18. Ulloa, L., M. Ochani, H. Yang, M. Tanovic, D. Halperin, R. Yang, C. J. Czura, M. P. Fink, and K. J. Tracey. 2002. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99:12351.
19. Seger, R., and E. G. Krebs. 1995. The MAPK signaling cascade. FASEB J. 9:726.
20. Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cell. Signal. 13:85.
21. Martich, G. D., R. L. Danner, M. Ceska, and A. F. Suffredini. 1991. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J. Exp. Med. 173:1021.
22. Dinarello, C. A., and R. C. Thompson. 1991. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today 12:404.
23. Deriy, L. V., D. W. Beno, M. R. Uhing, V. A. Jiyamapa-Serna, and R. E. Kimura. 2002. Splenectomy ablates endotoxin-induced IFN-γ response in rats. Shock 17:312.
24. Wang, P., Z. F. Ba, and I. H. Chaudry. 1997. Mechanism of hepatocellular dysfunction during early sepsis: key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6. Arch. Surg. 132:364.
25. Bernhagen, J., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey, W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756.
26. Calandra, T., B. Echtenacher, D. L. Roy, J. Pugin, C. N. Metz, L. Hultner, D. Heumann, D. Mannel, R. Bucala, and M. P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6:164.
27. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341.
28. Keller, R., P. Joller, R. Keist, H. Binz, and P. H. van der Meide. 1988. Modulation of major histocompatibility complex (MHC) expression by interferons and microbial agents: independent regulation of MHC class II expression and induction of tumoricidal activity in bone marrow-derived mononuclear phagocytes. Scand. J. Immunol. 28:113.
29. Ucla, C., P. Roux-Lombard, S. Fey, J. M. Dayer, and B. Mach. 1990. Interferon-γ drastically modifies the regulation of interleukin 1 genes by endotoxin in U937 cells. J. Clin. Invest. 85:185.
30. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
31. Beutler, B., V. Tkacenko, I. Milsark, N. Krochin, and A. Cerami. 1986. Effect of γ-interferon on cachectin expression by mononuclear phagocytes: reversal of the lpsd (endotoxin resistance) phenotype. J. Exp. Med. 164:1791.
32. Miles, R. H., T. P. Paxton, D. J. Dries, and R. L. Gamelli. 1994. Interferon-γ increases mortality following cecal ligation and puncture. J. Trauma 36:607.
33. Doherty, G. M., J. R. Lange, H. N. Langstein, H. R. Alexander, C. M. Buresh, and J. A. Norton. 1992. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J. Immunol. 149:1666.
34. Heinzel, F. P. 1990. The role of IFN-γ in the pathology of experimental endotoxemia. J. Immunol. 145:2920.
35. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
36. Newport, M. J., C. M. Huxley, S. Huston, C. M. Hawrylowicz, B. A. Oostra, R. Williamson, and M. Levin. 1996. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941.
37. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon-γ receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 179:1437.
38. 2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc. Natl. Acad. Sci. USA 95:14429.
39. Feng, J., Z. Yan, A. Ferreira, K. Tomizawa, J. A. Liauw, M. Zhuo, P. B. Allen, C. C. Ouimet, and P. Greengard. 2000. Spinophilin regulates the formation and function of dendritic spines. Proc. Natl. Acad. Sci. USA 97:9287.
40. Zhang, M., T. Caragine, H. Wang, P. S. Cohen, G. Botchkina, K. Soda, M. Bianchi, P. Ulrich, A. Cerami, B. Sherry, and K. J. Tracey. 1997. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J. Exp. Med. 185: 1759.
41. Bianchi, M., P. Ulrich, O. Bloom, M. Meistrell, G. A. Zimmerman, H. Schmidtmayerova, M. Bukrinsky, T. Donnelley, R. Bucala, and B. Sherry. 1995. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1:254.
42. Hommes, D., B. van den Blink, T. Plasse, J. Bartelsman, C. Xu, B. Macpherson, G. Tytgat, M. Peppelenbosch, and S. Van Deventer. 2002. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122:7.
43. Kotenko, S. V., and S. Pestka. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19:2557.
44. Bright, J. J., C. Du, and S. Sriram. 1999. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J. Immunol. 162:6255.
45. Gardella, S., C. Andrei, D. Ferrera, L. V. Lotti, M. R. Torrisi, M. E. Bianchi, and A. Rubartelli. 2002. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3:955.5.
46. Robinson, B. W., T. L. McLemore, and R. G. Crystal. 1985. γ-Interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J. Clin. Invest. 75:1488.
47. Fultz, M. J., S. A. Barber, C. W. Dieffenbach, and S. N. Vogel. 1993. Induction of IFN-γ in macrophages by lipopolysaccharide. Int. Immunol. 5:1383.
48. Albina, J. E., J. A. Abate, and W. L. Henry, Jr. 1991. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-γ in the induction of the nitric oxide-synthesizing pathway. J. Immunol. 147:144.
49. Langermans, J. A., M. E. Van der Hulst, P. H. Nibbering, P. S. Hiemstra, L. Fransen, and R. Van Furth. 1992. IFN-γ-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-α. J. Immunol. 148:568.
50. Mannick, J. B., C. Schonhoff, N. Papeta, P. Ghafourifar, M. Szibor, K. Fang, and B. Gaston. 2001. S-Nitrosylation of mitochondrial caspases. J. Cell Biol. 154:1111.
51. Allendoerfer, R., and G. S. Deepe, Jr. 1998. Blockade of endogenous TNF-α exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol. 160:6072.
52. Czura, C. J., H. Wang, and K. J. Tracey. 2003. TNF. In The Cytokine Handbook. A. Thomson and M. T. Lotze, eds. Academic, Oxford. In Press.
53. Kokkola, R., E. Sundberg, A. K. Ulfgren, K. Palmblad, J. Li, H. Wang, L. Ulloa, H. Yang, X. J. Yan, N. Chiorazzi, et al. 2002. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46:2598.
54. Lee, J. C., S. Kumar, D. E. Griswold, D. C. Underwood, B. J. Votta, and J. L. Adams. 2000. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47:185.
55. Fijen, J. W., J. G. Zijlstra, P. De Boer, R. Spanjersberg, T. J. Cohen, T. S. Van Der Werf, J. J. Ligtenberg, and J. E. Tulleken. 2001. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124:16.
56. Song, G. Y., C. S. Chung, D. Jarrar, I. H. Chaudry, and A. Ayala. 2001. Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock 15:42.
57. Badger, A. M., D. E. Griswold, R. Kapadia, S. Blake, B. A. Swift, S. J. Hoffman, G. B. Stroup, E. Webb, D. J. Rieman, M. Gowen, et al. 2000. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43:175.
58. Underwood, D. C., R. R. Osborn, S. Bochnowicz, E. F. Webb, D. J. Rieman, J. C. Lee, A. M. Romanic, J. L. Adams, D. W. Hay, and D. E. Griswold. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. 279:L895.
59. Barone, F. C., E. A. Irving, A. M. Ray, J. C. Lee, S. Kassis, S. Kumar, A. M. Badger, R. F. White, M. J. McVey, J. J. Legos, et al. 2001. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. 296:312.
60. O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl):S121.
61. Greenlund, A. C., M. O. Morales, B. L. Viviano, H. Yan, J. Krolewski, and R. D. Schreiber. 1995. Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 2:677.
62. Min, W., J. S. Pober, and D. R. Johnson. 1998. Interferon induction of TAP1: the phosphatase SHP-1 regulates crossover between the IFN-α/β and the IFN-γ signal-transduction pathways. Circ. Res. 83:815.
63. Darnell, J. E. J., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
64. Saito H., Y. Morita, M. Fujimoto, M. Narazaki, T. Naka, and T. Kishimoto. 2000. IFN regulatory factor-I-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-I gene promoter by IFN-γ. J. Immunol. 164:5833.
65. Chesler, D. A., and C. S. Reiss. 2002. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13:441.
66. Rodig, S. J., M. A. Meraz, J. M. White, P. A. Lampe, J. K. Riley, C. D. Arthur, K. L. King, K. C. Sheehan, L. Yin, D. Pennica, et al. 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373.
67. Parganas, E., D. Wang, D. Stravopodis, D. J. Topham, J. C. Marine, S. Teglund, E. F. Vanin, S. Bodner, O. R. Colamonici, J. M. van Deursen, et al. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385.
68. Meraz, M. A., J. M: White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431.
69. Ochiai, K., E. Tanabe, C. Ishihara, M. Kagami, T. Sugiyama, M. Sueishi, N. Koya, and H. Tomioka. 1999. Role of JAK2 signal transductional pathway in activation and survival of human peripheral eosinophils by interferon-γ (IFN-γ). Clin. Exp. Immunol. 118:340.
70. Levitzki, A. 1999. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82:231.